Skip to content
DataLookout
Menu

NCT07136012

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events

StatusRecruiting
PhasePhase 3
SponsorAmgen
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 37 versions: 37 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 6 words
    • Trial sites expanded: 252 → 261 locations
  2. Minor Site details revised at 3 of 252 sitesv36
  3. Minor Study sites: 251 to 252v35
  4. Minor Study sites: 249 to 251v34
  5. Minor Study sites: 248 to 249v33
Show 31 earlier versionsHide 31 earlier versions
  1. Minor Site details revised at 3 of 248 sitesv32
  2. Minor Study sites: 247 to 248v31
  3. Minor Study sites: 245 to 247v30
  4. Minor Study sites revised (245)v29
  5. Minor Study sites: 244 to 245v28
  6. Minor Site details revised at 1 of 244 sitesv27
  7. Minor Study sites: 243 to 244v26
  8. Minor Study sites: 242 to 243v25
  9. Minor Study sites: 241 to 242v24
  10. Minor Study sites: 239 to 241v23
  11. Minor Study sites: 238 to 239v22
  12. Minor Study sites: 237 to 238v21
  13. Minor Study sites: 229 to 237v20
  14. Minor Study sites: 226 to 229v19
  15. Minor Study sites: 220 to 226v18
  16. Minor Study sites: 215 to 220v17
  17. Minor Study sites: 214 to 215v16
  18. Minor Study sites: 211 to 214v15
  19. Minor Study sites: 207 to 211v14
  20. Minor Study sites: 204 to 207v13
  21. Minor Study sites: 199 to 204v12
  22. Minor Study sites: 198 to 199v11
  23. Minor Study sites: 187 to 198v10
  24. Minor Study sites: 182 to 187v9
  25. Minor Study sites: 161 to 182v8
  26. Minor Study sites: 145 to 161v7
  27. Minor Study sites: 138 to 145v6
  28. Notable Primary and study completion dates: Mar 19, 2031 to Oct 20, 2031
    • Study sites: 120 to 138
    v5
  29. Minor Study sites: 107 to 120v4
  30. Minor Study sites: 95 to 107v3
  31. Minor Study sites: 56 to 95
    • Primary and study completion dates: Oct 18, 2031 to Mar 19, 2031
    • Start date changed from estimate of Sep 19, 2025 to Aug 22, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First
Timeframe: Up to approximately 6.2 years

Secondary (13)

Time to Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke, Whichever Occurs First
Time to Cardiovascular Death, Myocardial Infarction, Urgent Coronary Revascularization, or Ischemic Stroke, Whichever Occurs First
Percent Change From Baseline to Week 48 Lp(a) Levels
Time to Myocardial Infarction
Time to CHD Death or Myocardial Infarction, Whichever Occurs First
Show 8 moreShow less
Time to Urgent Coronary Revascularization
Time to Coronary Revascularization
Time to CHD Death
Time to Cardiovascular Death
Time to Death by any Cause
Time to Ischemic Stroke
Serum Concentration of Olpasiran
Number of Participants with Treatment Emergent Adverse Events (TEAEs)

Arms and interventions

OlpasiranExperimental

Participants will receive subcutaneous (SC) olpasiran.

PlaceboPlacebo comparator

Participants will receive SC placebo.

Drugs: Olpasiran, Placebo

Sites

261 sites in 4 countries

United States 206, Canada 25, Australia 22, China 8